Clinical Trials Browser

Terminated × Neuroendocrine Tumors × Nivolumab × Clear all

NCT03420521 2024-01-09

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Phase 2 Terminated

9 enrolled 17 charts

Carcinoid Tumor, Neuroendocrine Tumors